Topics

Obesity Research
Weight-loss drug Contrave wins FDA approval on second try
Weight-loss drug Contrave wins FDA approval on second try

The U.S. Food and Drug Administration announced the approval Wednesday of the new weight-loss drug Contrave, a mix of antidepressant and alcohol dependence medications. The drug, which is intended to be used along with a low-calorie diet and exercise regimen, is approved for use in obese adults (body mass index of 30 or greater) or overweight adults (BMI of 27 or greater) who also suffer a weight-related condition, such as high blood pressure or Type 2 diabetes, according to regulators. The medication, which is manufactured by Orexigen Therapeutics Inc. of La Jolla, combines the drugs naltrexone, which is used to treat alcohol and opioid dependence, and the drug bupropion, which is...

Loading